TYK Medicines’ EGFR inhibitor demonstrates promising results in lung cancer patients with brain metastases. Tagrisso and asandeutertinib have shown activity in EGFR-mutated NSCLC with central nervous system metastases. In the Phase III FLAURA 1 trial, patients on Tagrisso had a median progression-free survival of 15.2 months, outperforming standard therapy with another EGFR inhibitor. Additionally, the […]
Tag: egfr
Breakwater Trial: Braftovi Enhances Survival in BRAF V600E CRC
In the Phase III BREAKWATER Trial, a Braftovi-based regimen demonstrated improved survival outcomes in patients with metastatic colorectal cancer (CRC) harboring the BRAF V600E mutation. Encorafenib, a potent and selective BRAF inhibitor, exerts antiproliferative and apoptotic effects in tumor cells with BRAF V600E mutations. Unlike other BRAF inhibitors, Encorafenib has prolonged pharmacodynamic activity. In colorectal […]
